Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study.
Julio García-SuárezJavier de la CruzÁngel CedilloPilar LlamasRafael DuarteVíctor Jiménez-YusteJosé Ángel Hernández-RivasRodrigo Gil-MansoMi KwonPedro Sánchez-GodoyPilar Martínez-BarrancoBlanca Colás-LahuertaPilar HerreraLaurentino Benito-ParraAdrián AlegreAlberto VelascoArturo MatillaMaría Concepción Aláez-UsónRafael Martos-MartínezCarmen Martínez-ChamorroKeina Susana-QuirozJuan Francisco Del CampoAdolfo de la FuenteRegina HerráezAdriana PascualElvira GómezJaime Pérez-OteyzaElena RuizArancha AlonsoJosé González-MedinaLucía Núñez Martín-BuitragoMiguel CanalesIsabel González-GascónMaría Carmen Vicente-AyusoSusana ValencianoMaría García RoaPablo Estival MonteliuJavier López-JiménezCristián Escolano EscobarJavier Ortiz-MartínJosé Luis Diez-MartinJoaquin Martinez Lopeznull nullPublished in: Journal of hematology & oncology (2020)
In this series of patients with hematologic malignancies and COVID-19, mortality was associated with higher age, more comorbidities, type of hematological malignancy and type of antineoplastic therapy. Further studies and long-term follow-up are required to validate these criteria for risk stratification.